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Human /I-lipotropin isolated in Hungary from frozen pituitary glands was purified by high-performance 
liquid chromatography in Canada. The amino acid sequence of the first 30 residues was determined. 
Trypsin, trypsinlpapain, and trypsinlthermolysin fragments were obtained for the disputed region con- 
taining residues 9-25 of /I-lipotropin. Their amino acid composition and sequence established beyond 
doubt that only one human /&lipotropin sequence is present. These results suggest the presence of only 
one gene coding for human pro-opiomelanocortin, the precursor of adrenocorticotropin and P-endorphin 
and resolve the controversy over the sequence of human fi-lipotropin. 
Human /3-lipotropin Sequence HPLCpurification 
1. INTRODUCTION 
It is now well-established that /3-lipotropin (p- 
LPH) and adrenocorticotropin (ACTH) are part of 
a common precursor in various species [l-4], 
called pro-opiomelanocortin [4]. The complete 
amino acid sequence of the various human seg- 
ments isolated has also been reported. These in- 
clude the amino-terminal fragment l-76 [5,6], the 
joining peptide [7], ACTH [S], /I-LPH [9,10], y- 
LPH [l I] and /3-endorphin [ 12,131. The human 
pro-opiomelanocortin DNA sequence has been re- 
vised [14] and so has been the protein amino acid 
sequence of human /3-LPH [ 151. These two revised 
sequences are identical as the primary structure of 
/I-LPH is concerned. However, both reports [ 14,151 
disagree with the sequences in [lO,l l] and pro- 
posed by the Hungarian group (see footnote in 
\I 11) for residues 9-25 of the /I-LPH structure. It 
was originally thought that polymorphism might 
be the cause of such a controversy [14,151. This was 
likely since evidence for the presence of more than 
one gene coding for both rat [ 16,171 and porcine 
[ 181 pro-opiomelanocortin was presented. The pur- 
pose of this joint study was to reexamine the pos- 
sibility that human fi-LPHs prepared by the Hun- 
garian [9] and Canadian workers [ 151 originate 
from two different pro-opiomelanocortin genes. 
Crude human P-LPH and all the purified /?-LPH 
fragments were prepared in Hungary and the se- 
quence work was done in the Canadian laboratory. 
Our results confirm the sequence in [15], thus sug- 
gesting that the differences between the published 
sequences are more likely due to difficulrirs in 
polypeptide sequencing than to polymorphism of 
the human pro-opiomelanocortin gene. 
2. MATERIALS AND METHODS 
2.1. Isolation of human /3-LPH 
+ Visiting scholar from: Shanghai Institute of Materia 
Medica, Academia Sinicia, China 
t To whom reprint requests should be addressed 
/I-LPH was prepared as in [ 191. This preparation 
was then further purified by reverse-phase, high- 
performance liquid chromatography (HPLC) as 
shown in fig.1. The column used was a P-Bond- 
apak Cl8 (Waters Co. 0.39 X 30 cm). The HPLC 
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apparatus consisted of two Beckman 110A pumps, 
a model 450 controler, a Hitachi variable wave- 
length spectrophotometer and a Waters model 730 
data module. Elution was made using a linear gra- 
dient of 2-propanol and 0.1% trifluoroacetic acid 
(TFA) from 20-60s in 60 min at 1 ml/min. Ab- 
sorbance was read at 235 nm (see fig.1). 
2.2. Purification of trypsin/papain and trypsinl 
thermolysin fragments of human P-LPH 
The large tryptic fragment (residues 9-37) was 
purified by chromatography on a Sephadex G-25 
column of the tryptic digest of human /J-LPH (see 
[IO]) and then by high-voltage paper elec- 
trophoresis at pH 5.0 (see method in [20]). Diges- 
tion of this fragment with papain (Sigma, type III) 
was performed in 0.1 M pyridine acetate at pH 5.5 
containing 5 mM EDTA and 5 mM dithiothreitol, 
at 1:20 (w/w) of enzyme’/peptide at 37°C for 3 h. 
Digestion with thermolysin (Serva, 3 X crystal- 
lized) was carried out with 1: 100 enzyme/substrate 
(w/w), in 0.1 M NH4HC03 (pH 8.0) at 37°C for 
3 h. The fragments were separated by two-dimen- 
sional paper electrophoresis at pH 5.0 and pH 2.0 
as in [9,20]. 
2.3. Amino acid analysis 
Amino acid analysis of purified trypsinlpapain 
and trypsin/thermolysin fragments of human /3- 
LPH was carried out on an updated Beckman 
120C amino acid analyser following 24 h hydro- 
lysis using 5.7 mM HCl at 108°C. Quantitation of 
sample amount of the papaic and thermolysin 
fragments was done by amino acid analysis in 
order to calculate the sequence yields of these frag- 
ments (see table 1). 
2.4. Sequence determination 
Automated Edman degradations were per- 
formed on a Beckman 890C sequenator equipped 
with a Sequemat P-6 autoconverter using a 0.3 M 
Quadrol program (Beckman no. 121178) and 3 mg 
Polybrene (Aldrich) [6]. Following 4 dummy cy- 
cles, 0.3 mg HPLC purified human P-LPH (see 
tig.lC, peak dl) were applied to the sequenator 
cup and double coupling performed for the first 
cycle only. The sequencing was extended to 30 
cycles. For papain and thermolysin fragments the 
amounts deposited on the sequenator cup, based 
on quantitative amino acid analysis are shown in 
268 
table 1. Phenylthiohydantoin (PTH) amino acids 
were identified and quantitated by HPLC as in [6]. 
3. RESULTS 
The HPLC purification of human fl-LPH eluted 
from the CM-Sephadex column [19] is shown in 
fig,l. Based on previous work [ 151, the elution 
position of human fi-LPH coincided with peak d 
(fig.lA). Upon repurification of material under 
peak d twice, using the same column and gradient 
elution (fig.lB,C), a homogeneous preparation of 
human fi-LPH was obtained (peak d, fig. 1 C) and 
used for sequencing studies. The sequenator PTH 
yields of each amino acid obtained from the mat- 
erial under peak dl (fig.lC) are shown in fig.2. The 
deduced sequence of the first 30 residues is shown 
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Fig. I. Purification of human /3-LPH by reverse-phase, 
high-performance liquid chromatography: (A) prelimin- 
ary purification of human /I-LPH; (B,C) the repurifica- 
tion on HPLC under same conditions as in (A); ( - - -) 
linear gradient of 2-propanol used. 
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Fig.2. Yield of each PTH-amino acid obtained during the sequence of human /I-LPH, as a function of sequencer cycle 
number. The numbers above each peak denote the assigned sequence position of that particular residue. 
Table 1 
Amino acid composition and deduced sequences of papaic and thermolysin 
fragments of human /I-LPH 
Amino 
acid 
ASP 
Ser 
Glu 
Pro 
G’Y 
Ala 
Leu 
His 
Papaic fragments Thermolysin 
fragments 
(8/lS9) (2S71) (2S8) (2S9) (82a4) (82a5) 
4.1 (4) 4.1 (4) 4.0 (4) 4.3 (4) 5.0 (5) 5.2 (5) 
- 1.0 (1) - 
1.0 (1) 1.4-(L) 1.9(2) 1.1-(L) 3.2 (3) 2.2 (2) 
1.8 (2) 1.5 (2) 1.6 (2) 1.6 (2) 1.9 (2) 2.1 (2) 
5.2 (5) 5.3 (5) 5.4 (5) 5.2 (5) 4.7 (5) 5.0 (5) 
2.1 (2) 2.5 (3) 2.8 (3) 2.3 (2) 3.7 (4) 3.9 (4) 
- - _ - 1.2 (1) - 
_ - - - 0.4 (1) - 
Corresponding human 9-22 9-23 9-24 9-22 9-30 9-26 
/&LPH peptide 
Fragments identiti- e f i h d g 
cation in fig.3 
Residues confirmed 9-22 9-18 9-11 9-13 9-23 9-17 
by sequence 
Sequenced sample 4 2 2 2 8 15 
amount (nmol) 
Sequenator yield 11% 18% 10% 10% 31% 23% 
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in fig.3 (line c). It is seen that the sequence of all 30 
residues is identical to that reported either for a 
human /?-LPH preparation [15], or deduced from 
the revised DNA sequence of human pro- 
opiomelanocortin [ 141. 
To reconfirm beyond doubt that the sequence 
obtained for this preparation is identical with that 
in [ 151, trypsin/papain and trypsin/thermolysin 
fragments of human /I-LPH originating from the 
disputed sequence region were also analyzed. The 
amino acid composition of these trypsin/papain 
and trypsin/thermolysin fragments is shown in 
table 1. It can be seen that the amino acid com- 
position of all the fragments obtained tit the re- 
ported human /3-LPH sequence [15] and that ob- 
tained in this work (fig.3, line c) for residues 9-30. 
Moreover, each papain and thermolysin fragment 
was sequenced. The 10% amounts of some frag- 
ments available (fragments h, i, table 1) allowed 
the identification of only few amino-terminal resi- 
dues. For those which were available in large 
quantities (fragments d-g, table l), sequencing 
could be extended for lo-15 residues and in the 
case of fragment e up to the COOH-terminal resi- 
due. The yields obtained although low (lo-31%) 
could be explained by the possible extraction 
losses of these peptides during sequencing, due to 
their small size. Indeed as the peptide size and 
amount available are larger, the sequenator yield 
is higher (cf. yields of fragments d and h in table 
1). Nevertheless, in all cases the partial sequences 
obtained are identical to that reported earlier for 
human /?-LPH [ 14,151. 
4. DISCUSSION 
The data in fig.3 and table 1 clearly show that 
the sequence of human P-LPH obtained from the 
Hungarian laboratory [9,19,20] is identical with 
that reported by the Canadian group [ 151. Further- 
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Fig.3. Confirmed human /I-LPH amino acid sequence: (a) protein sequence determined in 1151; (b) DNA sequence 
determined in [ 141; (c) protein sequence of purified human /I-LPH in this work (see f&.1,2); (d) trypsin/thermolysin 
fragment of human /I-LPH, 82a4; (e) trypsin/papain fragment of human /I-LPH, 8/ 1 S8; (f) trypsin/papain fragment of 
human /I-LPH, 2S71; (g) trypsin/thermolysin fragment of human /J-LPH, 82a5; (h) trypsin/papain fragment of human 
/I-LPH, 2S9; (i) trypsin/papain fragment of human /I-LPH 2S8; (i) protein sequence deduced in [ 10,l I]; amino acid 
residues differing from a, b are boxed in. In all other positions, the sequence reported in [ 10,l l] is identical to that in 
[ 14,151. The amino acid composition of the fragments is shown in table 1. (4) represents residues identified by 
sequence; (-) not sequenced residues due to fall off in yield during sequencing. 
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more, this human /J-LPH sequence is the same as 
that deduced from the revised DNA sequence of 
the gene coding for human /?-LPH [ 141. 
Of course, it is still possible that the amino acid 
sequence, between residues 9-22, of human /3- 
LPH isolated in [lo] is different from that of 
human &LPHs obtained by our laboratories, inde- 
pendently. This possibility is, however, rather un- 
likely. In this regard it is interesting to note that 
the amino acid composition of a thermolysin frag- 
ment, Thl (containing residues 9-24) isolated in 
[lo] is identical with that of a papaic fragment, 2% 
(i) included in table 1 of this paper. Furthermore, 
it might well be that one of the key-fragments, Pl, 
originally assigned to positions 9- 16 in [lo], is ac- 
tually a fragment of double size, with a composi- 
tion indistinguishable from that of 2S71 or 2S9 in 
table 1 here. To further illustrate this kind of diff- 
culty in locating the enzymic fragments purely on 
the basis of amino acid composition and partial 
sequence data, it is worth mentioning that Graf 
and coworkers had originally thought that all the 
papaic and thermolysin fragments (except 8/ 1 S8) 
in table 1 contain only 1 proline instead of 2. A 
preliminary sequence proposal by the latter group 
was based on this erroneous assumption (see foot- 
note in [ 111). 
Indeed, technical problems of determining the 
amino acid sequence, between residues 9-22, of 
human fi-LPH (see fig.3) by classical fragmenta- 
tion and against Edman-dansyl methods appear 
to be quite serious. Apparently, there are no tryp- 
sin, chymotrypsin, papain, thermolysin and pepsin 
sensitive peptide bonds within this sequence region 
to obtain smaller overlapping fragments by these 
enzymes. Furthermore, unless quantitative se- 
quencing procedures are employed, qualitative 
data by the Edman-dansyl procedure may be dif- 
ficult to interpret, in view of the possible con- 
tamination of the fragments and also, in this par- 
ticular case, of a partial resistance of the repetitive 
Asp-Gly sequences against Edman degradation 
191. 
In conclusion, our comparative studies on two 
independently prepared human P-LPH prepara- 
tions, do not support the view of either the pres- 
ence of polymorphic variations in the /3-LPH 
sequence or that more than one gene code for 
human pro-opiomelanocortin, as suggested in 
[2,11,14,15]. Accordingly, the structures of all the 
segments isolated and sequenced of human pro- 
opiomelanocortin [5,8,12,13,15] agree perfectly 
with the structure deduced from the revised DNA 
sequence of this pluripotent precursor molecule 
[ 141. In contrast, at least two genes coding for pro- 
opiomelanocortin have been reported in some 
other species as rat [16,17], pig 1181 and salmon 
[21,22]. It has yet to be established that such multi- 
plicity of genes also exists for human pro- 
opiomelanocortin. 
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